Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290904 | 0.98 | EPHX1 (0.50) | EPHX1SPHK1CASP2DPP7ZDHHC20 | |
| Iodide SCHEMBL4399927 | 0.98 | EPHX1 (0.45) | EPHX1SPHK1CASP2DPP7ALDH1A1 | |
| Bromide SCHEMBL5326683 | 0.98 | EPHX1 (0.45) | EPHX1SPHK1CASP2DPP7ALDH1A1 | |
| SCHEMBL9415795 | 0.98 | EPHX1 (0.50) | EPHX1SPHK1CASP2DPP7ZDHHC20 | |
| SCHEMBL9290794 | 0.93 | — | — | |
| Iodide SCHEMBL11150659 | 0.91 | GRIN2D (0.41) | EPHX1SPHK1TSHR | |
| Hydrochloric Acid SCHEMBL9325329 | 0.91 | GRIN2D (0.41) | EPHX1SPHK1TSHR | |
| SCHEMBL14771505 | 0.85 | SMN1; SMN2 (0.40) | EPHX1SPHK1ALDH1A1 | |
| SCHEMBL88539 | 0.85 | EPHX1 (0.54) | EPHX1SPHK1CASP2DPP7ALDH1A1 | |
| SCHEMBL1272676 | 0.83 | EPHX1 (0.58) | EPHX1SPHK1CASP2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306170-A1 | SYNTHESIS OF TEGASEROD OR A SALT THEREOF | GENERICS UK LIMITED (GB) | 2009-12-10 | — | — | US | claimed |
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | claimed |
| US-20090306170-A1 | SYNTHESIS OF TEGASEROD OR A SALT THEREOF | GENERICS UK LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008077871-A1 | SALTS OF TEGASEROD | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939176-A1 | Salts of Tegaserod | Novartis AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| EP-1435932-A4 | INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS | MESSAGE PHARMACEUTICALS INC (US) | 2006-12-06 | — | — | EP | disclosed |
| WO-2006116953-A1 | A METHOD FOR THE PREPARATION OF TEGASEROD AND SLECTED SALTS THEREOF | ZENTIVA, A.S. (CZ) | 2006-11-09 | — | — | WO | disclosed |
| US-20060178519-A1 | Process for preparing tegaserod | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | US | disclosed |
| US-7001924-B2 | Inhibitors of RNase P proteins as antibacterial compounds | MESSAGE PHARMACEUTICALS (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2006002212-A1 | TEGASEROD HEMIMALEATE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-01-05 | — | — | WO | disclosed |
| EP-1435932-A2 | INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS | Message Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030134904-A1 | Inhibitors of RNase P proteins as antibacterial compounds | S.R. ONE, LIMITED | 2003-07-17 | — | — | US | disclosed |
| WO-2003024407-A2 | INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS | MESSAGE PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-4160754-A | Stable polymer gels | BAYER AKTIENGESELLSCHAFT (DE) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306170-A1 | SYNTHESIS OF TEGASEROD OR A SALT THEREOF | SLC10A2, VIP, GIPR | EPHX1 1349/4885SPHK1 686/4885CASP2 4293/4885 |
| US-20030134904-A1 | Inhibitors of RNase P proteins as antibacterial compounds | RNASEH1, RNASEL, SNRPA | EPHX1 4549/4885SPHK1 3829/4885CASP2 1708/4885 |
| US-20060178519-A1 | Process for preparing tegaserod | MLNR, MLN, UGT1A9 | EPHX1 152/4885SPHK1 3569/4885CASP2 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.